Biophytis Partners with Lynx Analytics for AI-Driven Drug Discovery

Biophytis SA, a biotechnology company focused on age-related diseases, has announced a strategic partnership with Lynx Analytics. This collaboration aims to accelerate the discovery of new drugs for sarcopenia using artificial intelligence. Sarcopenia, a condition affecting the elderly, currently has no FDA-approved treatments.

Biophytis aims to utilize Lynx's AI technologies to identify and optimize small molecule drugs that could preserve and regenerate muscle mass. This partnership merges Biophytis' disease biological expertise with Lynx's computational technology, creating a more efficient drug development process.

CEO Stanislas Veillet emphasizes the potential to reduce time and costs in drug development. Lynx's CEO, Gyorgy Lajtai, highlights tools that streamline the discovery process, aiming to deliver therapies faster to those in need.